MedTrace Logo

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

NCT02479399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11412

Last updated 2024-10-22

No results posted yet for this study

Summary

The objective of this survey is to confirm the safety of Suglat Tablets

Conditions

Interventions

DRUG

ipragliflozin

Tablets

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-17
Primary Completion
2018-10-16
Completion
2018-10-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02479399 on ClinicalTrials.gov